Home > Publications database > Relapse following FLT3 inhibitor cessation in FLT3-ITD-positive AML: lessons from two clinical cases. > print

001     309656
005     20260205152941.0
024 7 _ |a 10.1007/s00277-026-06776-w
|2 doi
024 7 _ |a pmid:41636849
|2 pmid
024 7 _ |a 0939-5555
|2 ISSN
024 7 _ |a 0006-5242
|2 ISSN
024 7 _ |a 1432-0584
|2 ISSN
037 _ _ |a DKFZ-2026-00288
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Georgi, Julia-Annabell
|b 0
245 _ _ |a Relapse following FLT3 inhibitor cessation in FLT3-ITD-positive AML: lessons from two clinical cases.
260 _ _ |a New York
|c 2026
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1770301773_2392441
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #NCTZFB9#
520 _ _ |a The clinical success of FLT3 inhibitors has led to their steadily increasing use in the treatment of acute myeloid leukemia (AML), both in the relapsed/refractory setting and as post-transplant maintenance. Despite their expanding application, there is currently no guidance on the optimal duration of therapy or the feasibility of discontinuation. In the maintenance context, current practice is largely based on trial protocols with predefined treatment periods, yet relapses after cessation have been documented. Similarly, in the relapsed/refractory setting, the management of long-term responders to FLT3-directed monotherapy lacks evidence-based guidance.We report two cases of FLT3-ITD AML patients with relapse after discontinuation of prolonged FLT3 inhibitor therapy, despite sustained remission prior to withdrawal. As such scenarios remain insufficiently characterized in the literature, these case vignettes are presented to highlight the unresolved challenge of defining the appropriate duration of FLT3 inhibitor therapy and to underscore the need for systematic evaluation to establish evidence-based strategies for safe discontinuation or extended administration.
536 _ _ |a 899 - ohne Topic (POF4-899)
|0 G:(DE-HGF)POF4-899
|c POF4-899
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a FLT3 inhibitor
|2 Other
650 _ 7 |a FLT3-ITD AML
|2 Other
650 _ 7 |a Gilteritinib
|2 Other
650 _ 7 |a Measurable residual disease (MRD)
|2 Other
650 _ 7 |a Post-transplant maintenance
|2 Other
650 _ 7 |a Relapse
|2 Other
650 _ 7 |a fms-Like Tyrosine Kinase 3
|0 EC 2.7.10.1
|2 NLM Chemicals
650 _ 7 |a FLT3 protein, human
|0 EC 2.7.10.1
|2 NLM Chemicals
650 _ 7 |a Protein Kinase Inhibitors
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a fms-Like Tyrosine Kinase 3: antagonists & inhibitors
|2 MeSH
650 _ 2 |a fms-Like Tyrosine Kinase 3: genetics
|2 MeSH
650 _ 2 |a Leukemia, Myeloid, Acute: drug therapy
|2 MeSH
650 _ 2 |a Leukemia, Myeloid, Acute: genetics
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Protein Kinase Inhibitors: administration & dosage
|2 MeSH
650 _ 2 |a Protein Kinase Inhibitors: therapeutic use
|2 MeSH
650 _ 2 |a Recurrence
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
700 1 _ |a Röllig, Christoph
|b 1
700 1 _ |a Schetelig, Johannes
|b 2
700 1 _ |a Thiede, Christian
|b 3
700 1 _ |a Brückmann, Sascha
|b 4
700 1 _ |a Bornhäuser, Martin
|0 P:(DE-He78)2a9091646ed378ef030a77fd32aedf79
|b 5
700 1 _ |a Middeke, Jan Moritz
|b 6
773 _ _ |a 10.1007/s00277-026-06776-w
|g Vol. 105, no. 3, p. 82
|0 PERI:(DE-600)1458429-3
|n 3
|p 82
|t Annals of hematology
|v 105
|y 2026
|x 0939-5555
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)2a9091646ed378ef030a77fd32aedf79
913 1 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF4-890
|0 G:(DE-HGF)POF4-899
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-800
|4 G:(DE-HGF)POF
|v ohne Topic
|x 0
914 1 _ |y 2026
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2024-12-27
|w ger
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2024-12-27
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ANN HEMATOL : 2022
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-27
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-27
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-27
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2024-12-27
920 1 _ |0 I:(DE-He78)DD04-20160331
|k DD04
|l Koordinierungsstelle NCT Dresden
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)DD04-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21